News & Alerts
-
Aug- 2023 -18 August
Why Eligible Infants and Children Should Get The New RSV Medication – AAP
Respiratory Syncytial Virus (RSV) is a widespread viral infection that predominantly targets the respiratory system, particularly the lungs and airways.…
Read More » -
17 August
10 Free Online Courses for Drug Safety Specialists
The field of drug safety is of paramount importance in the pharmaceutical industry, ensuring that medicines are safe and effective…
Read More » -
17 August
Ipsen’s Sohonos (palovarotene) Capsules Approved by FDA for Managing Debilitating Bone Disorder
In a landmark development, Ipsen has officially received approval from the U.S. Food and Drug Administration (FDA) for its groundbreaking…
Read More » -
17 August
Ozempic’s Financial Triumphs and the CMS Negotiation Horizon
Ozempic, a prominent Type 2 diabetes drug, appears to be at the cusp of potential involvement with the Centers for…
Read More » -
16 August
UK NHS Joins Forces with IAOCR to Launch Clinical Trials Talent Taskforce
In a pivotal stride towards revitalizing the landscape of clinical research, the United Kingdom’s National Health Service (NHS) has forged…
Read More » -
16 August
GSK and Innoviva Forge Ahead to Combat Drug-Resistant Gonorrhea
The growing incidence of drug-resistant gonorrhea has raised alarm bells within the medical community, prompting both concern and urgency. In…
Read More » -
16 August
FDA Imposes Clinical Hold on Leukemia Drug Trial Following Participant’s Death
Following the unfortunate incident involving a participant’s death, a Massachusetts-based pharmaceutical company found itself facing a significant setback in its…
Read More » -
15 August
Prescription Price Surge: AARP Study Exposes Tripled Costs of Medicare Part D Drugs
The escalating cost of prescription drugs in the Medicare Part D program has raised significant concerns, as revealed by a…
Read More » -
15 August
Balancing Innovation and Access: The Debate Over EU’s Emergency Licensing Plan
The proposal by the European Commission to establish a compulsory licensing (CL) framework for medicines in emergency situations has faced…
Read More » -
15 August
Harmony Biosciences Expands with $200 Million Zynerba Acquisition
Neuroscience specialist Harmony Biosciences has recently reached an agreement to acquire Zynerba, a company focused on cannabidiol (CBD) products. This…
Read More »